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Abstract 33 
One major pathophysiological hallmark of Alzheimer’s disease (AD) is senile plaques 34 
composed of amyloid β (Aβ). In the amyloidogenic pathway, cleavage of the amyloid precursor 35 
protein (APP) is shifted towards Aβ production and soluble APPβ (sAPPβ) levels. Aβ is known 36 
to impair synaptic function; however, much less is known about the physiological functions of 37 
sAPPβ. The neurotrophic properties of sAPPα, derived from the non-amyloidogenic pathway 38 
of APP cleavage, are well-established, whereas only a few, conflicting studies on sAPPβ exist. 39 
The intracellular pathways of sAPPβ are largely unknown. Since sAPPβ is generated alongside 40 
Aβ by β-secretase (BACE1) cleavage, we tested the hypothesis that sAPPβ effects differ from 41 
sAPPα effects as a neurotrophic factor. We therefore performed a head-to-head comparison of 42 
both mammalian recombinant peptides in developing primary hippocampal neurons (PHN). We 43 
found that sAPPα significantly increases axon length (p = 0.0002) and that both sAPPα and 44 
sAPPβ increase neurite number (p < 0.0001) of PHN at 7 days in culture (DIV7) but not at 45 
DIV4. Moreover, both sAPPα- and sAPPβ-treated neurons showed a higher neuritic complexity 46 
in Sholl analysis. The number of glutamatergic synapses (p < 0.0001), as well as layer thickness 47 
of postsynaptic densities (PSDs), were significantly increased, and GABAergic synapses 48 
decreased upon sAPP overexpression in PHN. Furthermore, we showed that sAPPα enhances 49 
ERK and CREB1 phosphorylation upon glutamate stimulation at DIV7, but not DIV4 or 50 
DIV14. These neurotrophic effects are further associated with increased glutamate sensitivity 51 
and CREB1-signaling. Finally, we found that sAPPα levels are significantly reduced in brain 52 
homogenates of AD patients compared to control subjects. Taken together, our data indicate 53 
critical stage-dependent roles of sAPPs in the developing glutamatergic system in vitro, which 54 
might help to understand deleterious consequences of altered APP shedding in AD patients, 55 
beyond Aβ pathophysiology. 56 
Keywords: sAPP, AD, neuronal plasticity, neurodevelopment, CREB-1 signaling 57 
Research highlights:  58 
- sAPPα and sAPP have a critical stage-dependent role in the developing glutamatergic 59 
system in vitro 60 
- sAPPβ impacts in a different manner on the developing glutamatergic system compared 61 
to sAPP 62 
- Effects of sAPPα are associated with CREB-1 signaling 63 
List of abbreviations: 64 
Aβ, amyloid β; AD, Alzheimer’s disease; ADAM, A Disintegrin And Metalloproteinase (α-secretase); 65 
APP, amyloid precursor protein; AMPA-R, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 66 
receptor; BACE, β-site of APP cleavage enzyme (β-secretase); BDNF,  brain-derived neurotrophic 67 
factor; CNS, central nervous system; CREB, cAMP-response element binding protein; CSF, 68 
cerebrospinal fluid; DIV, days in vitro; EGFP,  enhanced green fluorescent protein; GABA, γ-69 
Aminobutyric acid; HRP, horse-radish peroxidase; LOAD, late-onset Alzheimer’s disease; LSM, laser-70 
scanning-microscope; LTP, long-term potentiation; NMDA-R, N-methyl-D-aspartate receptor; PCR, 71 
polymerase chain reaction; PHN,  primary hippocampal neuron; PSD, postsynaptic density; 72 
sAPP, soluble amyloid precursor protein; TEM, transmission electron microscopy 73 
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Introduction 88 
Besides being a central molecule in Alzheimer’s disease (AD) pathophysiology, amyloid 89 
precursor protein (APP) and its cleavage products are known to be major players in establishing 90 
and maintaining neuronal architecture (Nicolas and Hassan, 2014). Depending on whether α- 91 
or β-secretase (BACE1) cleaves first, subsequent APP cleavage by γ-secretase fosters or 92 
precludes the generation of the neurotoxic amyloid β (Aβ) fragment (Prox et al., 2012). 93 
Alongside failure of Aβ clearance mechanisms and missense mutations in presenilin 1 or 2 94 
genes, a shift in proteolytic APP processing towards BACE1 cleavage in AD patients that leads 95 
to gradually rising Aβ42 levels in the brain and therefore causing neuronal death is a well 96 
described hypothesis (Selkoe and Hardy, 2016). Besides the increased Aβ42 and soluble APPβ 97 
(sAPPβ) production, less sAPPα is also generated. 98 
In contrast to the deleterious effects of Aβ on neurons, the soluble APPα cleavage product 99 
(sAPPα) is known to have neurotrophic or synaptic plasticity enhancing characteristics, as 100 
shown by increase of long-term potentiation (LTP) (Taylor et al., 2008). sAPPα, but also sAPPβ 101 
levels seem to be decreased  in cerebrospinal fluid (CSF) of AD patients (Colciaghi et al., 2004; 102 
Hock et al., 1998; Lannfelt et al., 1995). BACE1 inhibition, which is a potential disease-103 
modifying therapy for AD, leads to decreased sAPPβ levels in the CSF of treated subjects 104 
(Kennedy et al., 2016). Interestingly, a missense mutation within the gene encoding for the 105 
major α-secretase, ADAM10, resulting in attenuated activity has been recently associated with 106 
late-onset AD (LOAD) (Suh et al., 2013). Both findings can therefore lead to an imbalance of 107 
soluble APP cleavage products in the central nervous system (CNS). Until now, it has not been 108 
known how APP influences neural development and adult brain function or whether loss of 109 
these functions can account for AD pathophysiology. Hence, deciphering the physiological 110 
functions of both sAPP forms is of crucial importance. 111 
In neuronal cell culture, it has been shown that sAPPα interacts with the p75 neurotrophin 112 
receptor to stimulate neurite outgrowth (Hasebe et al., 2013). Furthermore, sAPPα and sAPPβ 113 
decrease cell adhesion and thereby decrease dendrite outgrowth and increase axon outgrowth 114 
(Chasseigneaux et al., 2011). Neuroprotective effects are also described for sAPPα as it could 115 
be shown that it protects hippocampal neurons against Aβ induced oxidative injury (Goodman 116 
and Mattson, 1994) and proteasomal stress (Copanaki et al., 2010). Moreover, sAPPα has been 117 
shown to extenuate established synaptic and cognitive deficits in the APP/PS1∆E9 AD mouse 118 
model (Fol et al., 2015). Another study generated a sAPPα-knock-in mouse to show that sAPPα 119 
is sufficient to rescue the abnormalities of APP-deficient mice, including reductions in brain 120 
weight and the impairment in spatial learning and LTP (Ring et al., 2007). Conversely, there is 121 
one study published demonstrating that cleavage of sAPPβ under trophic-factor deprivation 122 
generates a cleavage product that is able to induce death receptor 6 signaling and thereby lead 123 
to cellular self-destruction (Nikolaev et al., 2009).  124 
Generally, effects of sAPPα on neurons are well established, whereas much less is known about 125 
sAPPβ function (Chasseigneaux and Allinquant, 2012). In addition, the intracellular pathways 126 
mediating the sAPP functions are also largely unknown. Since sAPPβ derives from 127 
amyloidogenic APP cleavage, we hypothesize that sAPPβ opposes neurotrophic sAPPα effects. 128 
Therefore, to further evaluate the roles of both sAPPs in neuronal development, we performed 129 
in this study a head-to-head comparison in developing primary hippocampal neurons at 130 
different time stages. 131 
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Materials and Methods 148 
Synthesis of recombinant sAPP peptides 149 
sAPPα and sAPPβ gene fragments were amplified by PCR with human APP695 cDNA as 150 
template. sAPPs were then N-terminally tagged with the APP secretory sequence, 8x histidine 151 
tag, and EGFP. Constructs were subcloned in pcDNA TM5/FRT (Invitrogen, Carlsbad, CA, 152 
USA) vector by NheI and ApaI restriction sites. The same construct (empty EGFP vector), 153 
without sAPP sequence (APP secretory sequence, 8x histidine tag, and EGFP), was used as a 154 
control peptide. For purification of sAPP and control proteins, Flp-InTMHEK293 cells were 155 
stably transfected (Flp-InTM system, Invitrogen, Carlsbad, CA, USA) with sAPPα, sAPPβ and 156 
the EGFP construct. Ni-NTA charged agarose beads (Qiagen Hilden, Germany, #30210) were 157 
added to the supernatant of the cultivated cells containing the his-tagged sAPP/EGFP fusion 158 
proteins. After overnight binding, beads were washed three times with low imidazol buffer (40 159 
mM imidazol) and sAPP/EGFP fusion proteins were subsequently eluted in high imidazol 160 
buffer (150 mM imidazol). For buffer exchange and protein concentration eluates were pooled 161 
and concentrated via 100 kDa cut-off columns (Millipore Darmstadt, Germany, #UFC810024). 162 
Proteins were recovered in PBS and analyzed qualitatively and quantitatively via SDS-PAGE, 163 
Western blot, BCA assay, and SimplyBlueTM SafeStain (Invitrogen, Carlsbad, CA, USA) (Fig. 164 
S1). 165 
Lentiviral plasmid design and vector production 166 
To generate infectious lentiviral particles, sequences of sAPPα and sAPPβ were cloned into 167 
pUltra Hot vector. sAPPα and sAPPβ gene fragments were amplified by PCR with the above-168 
mentioned sAPPα/β pcDNA TM5/FRT as template and  inserted into pUltra Hot vector by AgeI 169 
and NheI restriction sites. The expressed proteins were N-terminal fusion proteins with 170 
mCherry. pUltra Hot is a lentiviral vector backbone for bi-cistronic expression of the gene of 171 
interest and the fluorescent reporter mCherry under the control of a human ubiquitin promoter. 172 
pUltra Hot was a gift from Malcolm Moore (Addgene plasmid # 24130) and served as a control 173 
plasmid to induce viral stress on neurons. psPAX2 is a packaging plasmid encoding HIV-1 174 
gag/pol sequences under the control of a SV40 promoter. psPAX2 was a gift from Didier Trono 175 
(Addgene plasmid # 12260). pMD2.G is an envelope-expressing plasmid encoding for VSV-G 176 
glycoprotein under the control of a CMV promoter. pMD2.G was a gift from Didier Trono 177 
(Addgene plasmid # 12259). For the virus production, LentiX 293T cells (Takara Clontech, 178 
Mountain View, CA, USA) were co-transfected (calcium phosphate transfection method) with 179 
pUltra Hot, psPAX2 and pMD2.G. Six hours after transfection, the medium was changed to 180 
remove transfection reagent in the conditioned medium to which the virus is secreted. 48h after 181 
transfection conditioned medium was collected and filtered using a 0.2 µm sterile filter 182 
(Sarstedt, Nuembrecht, Germany). Conditioned medium was transferred to 38.5 ml Beckman 183 
Ultra-ClearTM tubes containing 3 ml 20% sucrose and spinned for 2.5 h at 4°C and 24,000 rpm 184 
in a Beckman SW32Ti swinging bucket rotor. Supernatant was discarded and virus was 185 
resuspended in DPBS, aliquoted and stored at -20°C until use. 186 
Preparation of primary hippocampal neurons 187 
Primary hippocampal neurons were prepared from brains of C57BL/6 embryonic mice (E18), 188 
as described previously (Kaech and Banker, 2006). Briefly, hippocampi were dissected from 189 
embryonic brains, the meninges were removed and the cells were dissociated by trypsinization 190 
(0.25%) for 20 min at 37 °C. The dissociated cells were resuspended in serum-free neurobasal 191 
medium (Gibco®, Invitrogen, Germany) supplemented with 10% B27 (Gibco®, Invitrogen, 192 
Germany) and 0.5 mM l-glutamine and seeded into poly-l-lysine-coated culture dishes at a 193 
density of 2.2x104 cells per cm2  for immunocytochemistry (grown on coverslips) and 6.6x104 194 
cells per cm2  for cell lysis. After 45 min, medium was replaced completely by the same 195 
medium, to reduce astroglial growth. Cells were maintained at 37°C in the presence of 5% CO2 196 
and 10% O2 in a humidified incubator. 197 
Morphometric analysis of PHN 198 
For morphometric analyzes of PHN, neurons were treated on DIV2 with 100 nM His-EGFP-199 
sAPPα/β or the His-EGFP control peptide, fixed on DIV7 and stained with anti-MAP2 and anti-200 
tau (For antibody specification see list below). To make sure that a substantial amount of sAPPs 201 
remains in the culture medium, we used 100nM His-EGFP-sAPP peptide to study long-term 202 
effects on neuronal culture. This concentration was previously tested by other groups in similar 203 
studies (Chasseigneaux et al., 2011). PHNs were fixed for 20 min in a 4% PFA solution in 204 
DPBS. Cells were then washed three times with PBS and subsequently permeabilized and 205 
blocked in Roti®-ImmunoBlock (Carl Roth, Karlsruhe, Germany) and 0.3% TritonX-100 for 1 206 
h at RT. Incubation with primary antibodies was performed overnight at 4°C with gentle 207 
shaking. The next day, cells were washed three times for 10 min with PBS. Incubation with 208 
secondary antibodies was performed for 1 h at RT with gentle shaking. Then cells were washed 209 
three times for 10 min with DPBS and embedded in Mowiol® 4-88 plus DABCO. To determine 210 
primary axon length, entire neurite length and neurite number, TIFF images of stained neurons 211 
were analyzed by ImageJ pluginsoftware NeuronJ. The longest tau positive neurite was 212 
considered as the primary axon in DIV7 neurons and the longest beta-III-tubulin neurite was 213 
considered as the primary axon in DIV4 neurons respectively. Sholl analysis (SHOLL, 1953) 214 
was performed semi-automatically using ImageJ pluginsoftware Concentric Circles. Briefly, a 215 
series of concentric circles was drawn around the soma with 20 µm between each circle. The 216 
number of intersections were counted manually and plotted against the distance from the soma. 217 
180 neurons from three independent cultures were sampled for DIV4 and DIV7 respectively. 218 
Determination of inhibitory and excitatory synapse number 219 
To determine synapse number, PHNs were fixed and stained at DIV14 using the same 220 
procedure as described in Morphometric analysis of PHN in the Materials & Methods section. 221 
Earlier time points were not suitable for synapse number determination due to immaturity of 222 
neurons. Cells were labelled with the primary antibodies anti-Homer1 as postsynaptic marker 223 
(SynapticSystems, Göttingen, Germany, #160003), anti-Bassoon as presynaptic marker (Enzo 224 
Lifesciences, Lörrach. Germany, #VAM-PS003) and anti-MAP2 as dendritic marker (EnCor 225 
Biotechnology, Gainesville, USA, #CPCA-MAP2) upon lentiviral mCherry-sAPP 226 
overexpression (DIV2 transduction). The transduction efficiency was about 95% (data not 227 
shown). As sAPP-peptides were secreted into the supernatant upon lentiviral overexpression, 228 
untransduced neurons were also used for quantification. Colocalization of both synaptic 229 
markers along the neurite indicate a mature glutamatergic synapse. All of these are well 230 
established synapse and neurite markers used for similar assays (Goetz et al., 2006; Grabrucker 231 
et al., 2011; Wang et al., 2016). Confocal images of immunostained neuronal cultures were 232 
acquired with a magnification of 63x (water immersion objective, pinhole aperture 1 m) by 233 
using a Zeiss LSM 710 Meta laser scanning microscope (Carl Zeiss, Jena, Germany), as 234 
described previously (Beyer et al., 2012). Quantification was performed semi-automatically by 235 
using ZEN blue edition (Zeiss, Oberkochen, Germany). The criteria for determing 236 
colocalization was an overlap of intensity peaks of homer1 and bassoon immunofluorescence 237 
staining. The counts of glutamatergic inputs were normalized to 10m dendrite length (MAP2 238 
staining) and are indicated as numbers in the results section. 239 
Western blot analysis 240 
Before lysis, neurons pre-incubated with His-EGFP-sAPP were briefly stimulated with 10 µM 241 
glutamate in wash buffer (for buffer composition see FLIPR-analysis part in Material & 242 
Methods section) for 30 s. After an additional 3 min in wash buffer, cells were lysed in brain-243 
extraction buffer (BEX: 25 mM Tris pH 8.0, 20 mM NaCl, 0.6% desoxycholate, 0.6 % Igepal 244 
CA‐630). Cell lysates (10-20 µg total protein, determined by BCA assay) were separated by 245 
lithium dodecyl sulphate (LDS)-polyacrylamide gel electrophoresis (NuPage Novex Bis-Tris 246 
4-12% gradient gels, Invitrogen) prior to electrophoretic transfer onto 0.2 µm pore size 247 
nitrocellulose membrane (GE Healthcare, Boston, USA, #10600001). The membranes were 248 
blocked with 5% non-fat dry milk for 1 h at room temperature. Overnight incubation at 4°C 249 
was performed for primary antibody binding (for used antibodies see below). The next day, 250 
blots were incubated for 1 h at room temperature with horseradish peroxidase-conjugated 251 
secondary antibodies prior to exposure to ECL Luminata Forte (Millipore, Darmstadt, 252 
Germany, #WBLUF0100). For detection of the corresponding non-phosphorylated proteins, 253 
blots were stripped with 0.1 M glycine, 1% SDS, 1% Tween-20 (pH 3.5) for 15 min at 37°C, 254 
followed by blocking in 5% non-fat dry milk and incubated with the antibodies corresponding 255 
to the total proteins as described above. Digitized images of the immunoblots were used for 256 
densitometric measurements with ImageJ. Relative levels of phosphorylated proteins were 257 
determined by normalization of the density of images from phosphorylated proteins with that 258 
of the total proteins on the same blot. 259 
Antibodies 260 
The following antibodies were purchased from commercial suppliers: Western blot: anti-261 
phospho-CREB Ser133 (Cell Signaling Technology, clone 8763, #9198) (1:1,000), anti-262 
phospho-p44/p42 MAPK (ERK1/2) Thr202/Tyr204 (Cell Signaling Technology, clone E10, 263 
#9106) (1:1,000), anti-CREB (Cell Signaling Technology, clone 86B10, #9104) (1:1,000), anti-264 
p44/p42 (ERK1/2) (Cell Signaling Technology, clone 86B10, #9104) (1:1,000), anti-beta III 265 
Tubulin (Abcam, #ab18207) (1:1,000). Immuncytochemistry (ICC): anti-VGlut1 266 
(SynapticSystems, #135304) (1:400), anti-VGAT (SynapticSystems, #131011) (1:400), anti-267 
Gephrin (SynapticSystems, #147011) (1:400), anti-Homer1 (SynapticSystems, #160003) 268 
(1:500), anti-Bassoon (Enzo Lifesciences, #VAM-PS003) (1:500), anti-MAP2 (EnCor 269 
Biotechnology, #CPCA-MAP2) (1:500), anti-beta III Tubulin (Neuromics, #MO15013) 270 
(1:500), anti-GAPDH (abcam, #ab9485). Western blot human samples: anti-human sAPPα 271 
(IBL International, clone 2B3, #11088), anti-human sAPPβ (IBL International, #18957). 272 
Secondary antibodies used for Western blot were HRP goat anti-mouse IgG (H+L) and HRP 273 
goat anti-rabbit IgG (H+L) (Invitrogen, 1:10,000). Secondary antibodies used for ICC were 274 
Alexa Fluor® 488/546/647 Goat anti-Rabbit/Mouse/Chicken IgG (H+L) (Invitrogen, 1:750). 275 
Electron-microscopical investigations 276 
Neurons were plated with a density of 6.6x104 cells per cm2.  After 14 days in culture, neurons 277 
were fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer with 1% sucrose (pH 7.3) and 278 
postfixed with 1% osmium tetroxide for 4 h. Cultures were then dehydrated through an 279 
increasing propanol series, stained with 2% uranyl acetate and embedded in epoxy resin (Epon 280 
812, Fluka, Germany). Ultrathin sections (70–80 nm) were cut with a diamond knife on a 281 
Reichert ultramicrotome and collected on 300- mesh grids. The sections were stained with lead 282 
citrate and examined at a voltage of 100 kV by using the transmission electron microscope 283 
JEM-1400 (Jeol, Akishima, Japan). Images were recorded with a resolution of 2,048 × 2,048 284 
pixels and a magnification of 50,000x using a Veleta digital camera (Olympus Soft Imaging 285 
Solutions GmbH, Münster, Germany) and the iTEM software (Olympus Soft Imaging Solutions 286 
GmbH, Münster, Germany). At least 20 images of PSDs from asymmetric synapses in different 287 
cells were acquired per condition and independent experiment. Single images of the synapse 288 
were taken to measure PSD thickness. The thickness was determined manually by using ImageJ 289 
to measure the thickness from electron dense areas at three different locations in each PSD 290 
(central, and left/right from the centre, orthogonal to the PSD). The three measured values were 291 
averaged and defined as PSD thickness for the measured synapse.  292 
FLIPR-analysis 293 
Intracellular Ca2+ changes were monitored using the FLIPRTetra fluorometric imaging plate 294 
reader (Molecular Devices, CA, USA). Before dyeloading, Neurobasal culture medium was 295 
removed. The neurons were washed three times with imaging buffer (NaCl 145 mM, KCl 5 296 
mM, CaCl2 2 mM, Glucose 25 mM, HEPES 12 mM, pH was adjusted to 7.4). After the last 297 
wash step, neurons were loaded with 2 µM Fluo-4 diluted in imaging buffer. Neurons were 298 
incubated for 45 min at 37°C. Then, neurons were washed three times with 180 µl imaging 299 
buffer left after the last wash step. Neurons were incubated for 15 min with 1nM His-EGFP-300 
sAPPα, His-EGFP-sAPPβ or the control peptide His-EGFP. We decided to use 1 nM of both 301 
sAPP forms and control peptide in the FLIPR experiments, since this concentration 302 
(concentration response curve with 0.01, 0.1, 1 and 10 nM) was previously tested by other 303 
groups in similar studies on Ca2+ mobilization (Furukawa et al., 1996a; Furukawa and Mattson, 304 
1998). Regarding long-term studies, to make sure that a substantial amount of sAPPs remains 305 
in the culture medium over the time course of the experiment, we used the supra-effective 306 
concentration of 100nM sAPP peptide to the study long-term effects of sAPPs on neuronal 307 
culture. This experiment was not aimed at defining exactly the minimal effective concentration, 308 
but rather to investigate mechanistically the long-term effects of sAPPs. Further, this 309 
concentration was previously tested successfully by other groups in similar experiments 310 
(Chasseigneaux et al., 2011). After recording the baseline for 10 s, 20 μl imaging buffer 311 
containing 100 µM glutamate (final concentration in wells was 10 µM) was added to the wells 312 
and the kinetic of the Ca2+ responses was measured on the FLIPR device for evaluation of 313 
intrinsic compound activity.  314 
Synaptoneurosome preparation 315 
Synaptoneurosomes and homogenates were prepared as described in Tai et al. 2012 (Tai et al., 316 
2012) using human end stage AD and control brain tissue provided by the Edinburgh Brain 317 
Bank. In brief, approximately 300 mg of Brodmann area 41/42 was homogenized in 1 ml of ice 318 
cold Buffer A (25 mM HEPES pH 7.5, 120 mM NaCl, 5 mM KCl, 1 mM MgCl2, and 2 mM 319 
CaCl2), supplemented with 2 mM dithiothreitol (DTT), protease inhibitors (roche complete 320 
mini) and phosphatase inhibitors (Millipore, 524629).  The homogenate was filtered through 2 321 
layers of 80 m nylon filter (NY8002500, Millipore), and a 200 l aliquot of this was saved as 322 
the crude homogenate. The saved aliquot was mixed with 140 l water, 60 l of 10% SDS and 323 
boiled for 5 minutes. To prepare the synaptoneurosomes the remainder of the homogenate was 324 
filtered through a 5 m filter (SLSV025NB, Millipore) and centrifuged at 1,000 g for 5 minutes. 325 
The supernatant was removed and the pellet was suspended in Buffer A and centrifuged again 326 
(1,000 g for 5 min). The supernatant was again removed and the resulting synaptoneurosome 327 
pellet was suspended in 400 l of Buffer B (50 mM Tris [pH 7.5], 1.5% SDS, and 2 mM DTT) 328 
and boiled for 5 min. 329 
 330 
Protein concentration was determined using a BSA assay (ThermoFisher, 23225) and 5 mg of 331 
protein from either synaptoneurosome or crude homogenate was loaded onto NuPAGE 4-12% 332 
Bis-Tris precast polyacrylamide 15 well gels (Invitrogen, Paisley, UK) along with molecular 333 
weight marker (Li-Cor, Cambridge, UK). Proteins were electro-transferred to nitrocellulose 334 
membrane (Bio-Rad, Hemel Hempstead, UK). Membranes were blocked using Odyssey 335 
Blocking Buffer (927-40000, LI-COR) diluted 1:1 in PBS. Primary antibodies were incubated 336 
overnight in block with gentle shaking. Proteins were visualized on an Odyssey infrared system 337 
using the appropriate 680 and 800 IR dye secondary antibodies (1:50,000, LI-COR Biosciences) 338 
and were analyzed using Odyssey software (LI-COR Biosciences). Patient demographic data 339 
are depicted in Table S1. 340 
Data analysis 341 
All statistical analyzes were carried out by GraphPad Prism 6.05. Data was tested for Gaussian 342 
distribution by the D’Agostino-Pearson omnibus normality test. For comparison of two groups, 343 
a Students t-test was used. When data was not normally distributed, the ranked values of two 344 
groups were tested for significant differences using a Mann-Whitney U-test. A Kruskal-Wallis 345 
test and Dunn’s post hoc test for multiple comparisons were used when more than two groups 346 
were tested for significant differences. Statistically significant differences in FLIPR analysis 347 
among different groups were determined using Two-Way ANOVAs with a Dunnett’s post-hoc 348 
test for multiple comparisons. The results are expressed as median (25th–75th percentile). 349 
As an integrative analysis over different distances the results of the Sholl analysis were analyzed 350 
in comparative regression experiments (Dünkler et al., 2015). A global regression model fitted 351 
to the samples of both groups (treated/untreated) was tested against a pair of group-wise models 352 
fitted individually to the curves treated or the untreated samples. The significance of a 353 
difference between the treated group and the untreated group was determined by a comparison 354 
of the least square errors of the global model and the pair of individual models (F-Test) (Lomax 355 
et al., 2012; Motulsky and Ransnas, 1987). The model types were selected via the Akaike 356 
information criterion (Burnham et al., 2002). They were chosen from a set of 10 predefined 357 
model types. The corresponding software (CuCompare) is available at http://sysbio.uni-358 
ulm.de/soft/CuCompare.  359 
 360 
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 367 
Results 368 
sAPP treatment of PHN affects neuronal morphology and complexity in a stage-369 
dependent manner 370 
To determine the differential effects of sAPPs on neuronal morphology and branching we 371 
produced recombinant proteins of human sAPP695 and sAPP695 in HEK293 cells. These 372 
bear all post-translational modifications observed in eukaryotic cells. PHNs were treated at 373 
DIV2 with 100 nM His-EGFP-sAPP or His-EGFP-sAPP and fixed and immunostained with 374 
MAP-2 and Tau at DIV7 or -III-tubulin at DIV4 respectively. His-EGFP-sAPP administration 375 
(100 nM) to PHN at DIV2 with fixation at DIV 4 did not lead to altered primary axon length 376 
(Fig. 1A), entire neurite length (Fig. 1B), and neurite number (Fig. 1C). The median lengths, 377 
25th and 75th percentiles are depicted in table 1. 378 
When PHNs were treated with the same concentration of His-EGFP-sAPP at DIV2 and fixed 379 
at DIV7, the median primary axon length was increased significantly by 21.5% upon His-380 
EGFP-sAPPα treatment (p = 0.0002) but not upon His-EGFP-sAPPβ treatment (Fig. 1 D). 381 
Morphometric analysis also revealed a significant increase in median neurite length per neuron 382 
(p < 0.0001) (Fig. 1E) and also in median neurite number by 50% upon His-EGFP-sAPPα and 383 
33.3% upon His-EGFP-sAPPβ treatment (p < 0.0001) (Fig. 1F). The median lengths, 25th and 384 
75th percentiles are depicted in table 1. The significant increase in neurite number upon His-385 
EGFP-sAPPα and His-EGFP-sAPPβ treatment raised the question if there is also alteration in 386 
neuritic ramification. To determine neuritic complexity at DIV7, Sholl analysis was performed. 387 
We plotted the number of intersections of neurites with each circle against the distance from 388 
the cell body (see scheme in Fig. 1G). This extensive analysis revealed a significant increase in 389 
neuritic arborization upon His-EGFP-sAPPα and His-EGFP-sAPPβ treatment (Fig. 1H) 390 
significant for distances from soma from 20 µm to 200 µm, p < 0.05). Further analysis revealed 391 
a distinct pattern of arborization for His-EGFP-sAPPα and His-EGFP-sAPPβ, with increased 392 
branching close to the soma for His-EGFP-sAPPα. Exemplary images of analysed neurons are 393 
shown in Fig. S2. 394 
Table 1. Summarized morphological analysis of primary hippocampal neurons 
 
4 DIV 
ctrl 
4 DIV 
sAPPα 
4 DIV 
sAPPβ 
Axon length [nm] 113.1 (86.14 – 146.5) 109.3 (77.41 – 139.2) 113.5 (35.19 – 153.8) 
Neurite length [nm] 226.2 (182.8 – 268.4) 220.0 (174.3 – 277.6) 242.6 (191.8 – 295.6) 
Neurite number 4 (3 – 5) 4 (3 – 5)  4 (3 – 5)  
    
 
7 DIV 
control 
7 DIV 
sAPPα 
7 DIV 
sAPPβ 
Axon length [nm] 324.4 (255.2 – 438.5) 394.1 (322.6 – 470.7)* 352.2 (283.1 – 445.3) 
Neurite length [nm] 1234.0 (868.8 – 1680.0) 1696.0 (1430.0 – 2174.0)* 1622.0 (1303.0 – 2095.0)* 
Neurite number 12 (9 – 16) 18 (14 – 23)* 16 (12.25 – 22)* 
Axon lengths, neurite lengths and neurite numbers are indicated as median (25th-75th percentile). Statistical 395 
significance is marked by an asterisk. *p < 0.0001, One-Way ANOVA, Kruskal-Wallis test, Dunn’s post-hoc test. 396 
 397 
Advanced glutamatergic synaptic architecture upon sAPP overexpression 398 
To test the hypothesis that the increased neuritic arborization of PHN upon His-EGFP-sAPP 399 
treatment at DIV7 (first mature synapses observed) is associated with an increased function of 400 
glutamatergic synapses, we determined the synapse number upon lentiviral sAPP 401 
overexpression and compared them with control neurons at DIV14, where synaptic maturation 402 
is well established. Use of the lentiviral expression system ensured a stable and brief secretion 403 
of sAPP to supernatant of neuronal cell culture from DIV2 to DIV14. Secretion of sAPP 404 
peptides to neuronal cell culture supernatant was verified by Western blot (Fig. S1). Using 405 
double staining for Homer1 (postsynaptic marker) and Bassoon (presynaptic marker) at DIV 406 
14, we were able to discriminate immature from mature glutamatergic synapses (Grabrucker et 407 
al., 2009). Colocalization of Homer1 and Bassoon indicated a fully developed excitatory 408 
synapse (Fig. 2A). We observed that 75% more mature glutamatergic synapses were developed 409 
until DIV14, when mCherry-sAPPα was overexpressed (p < 0.0001) and 25% more mature 410 
synapses when mCherry-sAPPβ (p < 0.0001) was stably secreted for 12 DIV in primary 411 
hippocampal neurons. The median number of mature glutamatergic synapses at DIV14 was 1.6 412 
(1.2–2.0) in the control condition, 2.8 (2.1–3.5) upon mCherry-sAPPα overexpression and 2.0 413 
(1.6–2.3) upon mCherry-sAPPβ overexpression (Fig. 2B). mCherry-sAPPα as well as mCherry-414 
sAPPβ overexpression resulted in a marked rightward shift in the frequency distribution of 415 
synapse numbers, indicating an increased number of colocalizations (Fig. 2C).  416 
To test the hypothesis that increased sAPP levels, leading to an increased number of 417 
glutamatergic synapses, also lead to alterations in the subsynaptic architecture, we determined 418 
PSD layer thickness from asymmetric synapses in mCherry-sAPP-overexpressing neurons by 419 
electron microscopy. Asymmetric synapses were distinguished from symmetric synapses. The 420 
former are excitatory in function and are formed by axon terminals that contain spherical 421 
synaptic vesicles and an electron-dense PSD (Fig. 2D, asterisks mark PSDs). We observed that 422 
PSDs of neurons exposed to higher extracellular sAPPα levels showed a 27.4% increase in 423 
median layer thickness compared to control neurons. PSDs of mCherry-sAPPβ-overexpressed 424 
neurons were not significantly changed. The median PSD strength of neurons was 14.6 nm 425 
(10.5–17.6 nm) in control, 18.6 nm (14.1–23.0 nm) after treatment with mCherry-sAPPα and 426 
14.0 nm (10.9–17.1 nm) after treatment with mCherry-sAPPβ (Fig. 2E). Increased exposure to 427 
mCherry-sAPPα led to a homogenous rightward shift in frequency distribution of PSD layer 428 
thickness (Fig. 2F). 429 
 430 
Increased neuritic arborization is associated with higher levels of activated markers of 431 
neuronal activity 432 
Since it has been previously described that sAPP levels are altered during aging and disease, 433 
we hypothesized that sAPPs can influence neuronal activity of maturated PHNs. To test, 434 
whether mature hippocampal neurons are responsive to sAPP effects mediated by the 435 
glutamatergic system in principal, neurons were loaded with a Ca2+-sensitive dye (Fluo4) and 436 
incubated for 15 min with 1 nM of His-EGFP control peptide, His-EGFP-sAPPα or His-EGFP-437 
sAPPβ at DIV14. Subsequent Ca2+-imaging by a FLIPR system revealed that both His-EGFP-438 
sAPPα and His-EGFP-sAPPβ administration increased glutamate (stimulation with 10 µM 439 
glutamate) induced cytoplasmatic Ca2+ levels in mature hippocampal neurons (Fig. 3A). 440 
Next we tested whether downstream Ca2+ signaling is also affected by long-term application of 441 
His-EGFP-sAPP peptides. We administered 100 nM His-EGFP control peptide, His-EGFP-442 
sAPPα or His-EGFP-sAPPβ to primary hippocampal neurons at DIV2 (lentiviral mCherry-443 
sAPP overexpression for DIV14 neurons). At DIV4, DIV7 or DIV14, hippocampal neuronal 444 
cultures were briefly stimulated with 10 µM glutamate for 30 s to induce neuronal activity in 445 
the glutamatergic system. Subsequent determination of p-ERK2 and p-CREB1 levels revealed 446 
that hippocampal cell cultures treated with 100 nM His-EGFP-sAPPα from DIV2 to DIV7 show 447 
significantly higher levels of phosphorylated ERK2 (78.4% increase, p = 0.02) (Fig. 3B) and 448 
CREB1 (300.1% increase, p = 0.01) (Fig. 3C) determined by Western blot (normalized to total 449 
levels or ERK2 or CREB1 respectively). By contrast, we did not see changes induced by His-450 
EGFP-sAPP administration upon glutamate stimulation of DIV4 or DVI14 neuronal cell 451 
cultures compared to treatment with the His-EGFP control peptide (Fig. 3B, C). To further 452 
elucidate the short-term effects of His-EGFP-sAPPα and His-EGFP-sAPPβ on the 453 
phosphorylation of CREB, SH-SY5Y cells were transfected with a FRET-based CREB1 454 
biosensor (ICAP) and pre-treated with 1nM His-EGFP-sAPPα and His-EGFP-sAPPβ. 455 
Ratiometric analysis of the FRET fluorophores revealed a significant increase in CREB1 456 
phosphorylation upon His-EGFP-sAPPα treatment 5 mins after glutamate stimulation (Fig. S3 457 
A). CREB1 phosphorylation level was unchanged upon His-EGFP-sAPPβ treatment (Fig. S3 458 
B). 459 
 460 
sAPP overexpression led to advanced glutamatergic architecture at DIV14 comparable to 461 
control treated DIV21 neurons but it suppresses the formation of GABAergic inputs 462 
sAPP effects may be limited to a subpopulation of synaptic terminals. We therefore asked to 463 
what extent glutamatergic, as opposed to GABAergic, synaptic terminals benefited from the 464 
presence of sAPPs in supernatant of neuronal culture medium. To answer this question, we 465 
transduced PHNs at DIV2 with mCherry-sAPPα-, mCherry-sAPPβ- or a mCherry-control-466 
lentivirus. At DIV14 and DIV21, we counted VGlut1 positive puncta along the dendrite as 467 
markers for the excitatory presynapse (Fig. 4A). VGAT1 was used as a marker for inhibitory 468 
synapses (Fig. 4C). Upon mCherry-sAPPα overexpression, DIV14 PHNs showed a significant 469 
increase in VGlut1 positive puncta (20%, p < 0.0001) normalized to 10 µm dendrite length 470 
compared to overexpression of the mCherry control construct (Fig. 4B). When mCherry-sAPPβ 471 
was overexpressed in primary neurons until DIV14, the median number of VGlut1 positive 472 
puncta was elevated by 20% (p < 0.0001). The median quantity of VGlut1 positive puncta at 473 
DIV14 was 1.5 (1.2 – 1.7) in the control, 1.8 (1.5–2.1) in the mCherry-sAPPα overexpressing 474 
neurons and 1.8 (1.5 – 2.1) upon mCherry-sAPPβ overexpression in primary hippocampal 475 
neurons. 476 
In contrast to glutamate-releasing presynapses, GABA-releasing terminals are inhibitory in 477 
function. To test whether synaptogenesis in general is elevated in the presence of exogenous 478 
sAPP, we next determined the number of GABA- versus glutamate-releasing terminals in 479 
DIV14 neurons in mCherry-sAPP-overexpressing hippocampal neurons (Fig. 4C). Upon 480 
mCherry-sAPPα overexpression, 32% less GABAergic terminals were developed compared to 481 
overexpression of the control construct (p < 0.0001). The number of GABA-releasing 482 
presynapses was also significantly reduced by 28% when developing neurons were exposed to 483 
mCherry-sAPPβ compared to the control peptide (p < 0.0001) (Fig. 4D). The median of 484 
absolute inhibitory presynapses were 1.0 (0.8–1.2) after mCherry-sAPPα, 1.0 (0.8–1.3) after 485 
mCherry-sAPPβ and 1.4 (1.2–1.7) upon mCherry-control construct overexpression. The 486 
calculated ratio of glutamatergic to GABAergic synaptic terminals was significantly increased 487 
by 76% upon mCherry-sAPPα and 72% after mCherry-sAPPβ overexpression (p < 0.001) (Fig. 488 
4E).  489 
To further test the hypothesis that neuronal development in vitro is advanced resulting from a 490 
neuronal network exposed to elevated sAPP levels, we transduced PHNs at DIV2 with a 491 
mCherry-control-lentivirus and counted VGlut1 and VGAT at DIV21 and compared them with 492 
DIV14 mCherry-sAPP-overexpressing neurons. We found that neurons overexpressing the 493 
control construct from DIV2 to DIV21 showed 27% (p < 0.0001) more VGlut1, but no 494 
significant change in the number of VGAT positive puncta compared to neurons overexpressing 495 
the control construct from DIV2 to DIV14 (Fig. 4B,D). The median count of VGlut1 positive 496 
puncta at DIV21 was 1.9 (1.6–2.2) (Fig. 4B) and 1.6 (1.3–1.9) (Fig. 4D) for VGAT positive 497 
puncta upon overexpression of the control construct. A proposed model of how sAPP could 498 
affect synapse development in vitro is depicted in Fig. 4F. 499 
 500 
sAPPα is decreased in AD brains and can be detected in human synaptoneurosomes 501 
Since we were able to show that sAPPα and sAPPβ have crucial functions in the development 502 
of the glutamatergic system in vitro and activity of the major α-secretase ADAM10 and BACE1 503 
activity seem to be altered in LOAD patients, we next asked whether sAPP levels are altered in 504 
homogenates and synaptoneurosomes of human post-mortem tissue of AD patients and control 505 
subjects. To do so, we enriched synaptoneurosomes from BA41/42 of end stage brain tissue by 506 
a previously reported method (Tai et al., 2012). Western blot analysis with a human sAPPα-507 
specific antibody revealed that sAPPα is significantly decreased by about 53% in brain 508 
homogenate of AD patients compared to control subjects (Fig. 5A, p = 0.007). We further 509 
observed a tendency of reduced sAPPα levels in synaptoneurosomes of AD patients (Fig. 5B, 510 
p = 0.128). We also tested if sAPPβ is detectable in human brains with a human sAPPβ specific 511 
antibody. We were not able to detect full length sAPPβ in human brain homogenates or 512 
synaptoneurosomes, but cleavage fragments (Fig. S4). Therefore, we did not quantify these 513 
Western blots. 514 
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 533 
Discussion 534 
Considering that levels of the soluble APP ectodomains, released by initial ADAM-10 or 535 
BACE1 cleavage, are altered in AD patients (Cuchillo-Ibañez et al., 2015; Holsinger et al., 536 
2004; Lannfelt et al., 1995; Palmert et al., 1990; Zetterberg et al., 2008), the natural in vivo 537 
function of sAPPs in the CNS are of pivotal interest. 538 
In this study, we investigated the impact of sAPPs on the glutamatergic system and the 539 
accompanying morphological changes in hippocampal neuronal cell culture side by side. We 540 
found that both sAPPβ and sAPPα stimulate the glutamatergic system in hippocampal neurons 541 
in vitro and regulate neuronal development and synapse formation in a stage-dependent fashion. 542 
Our study reports several important findings. First, both sAPPβ and sAPPα affect neuronal 543 
morphology and complexity in a stage-dependent manner in PHNs. Having structurally and 544 
functionally different processes that act as communication relay in the CNS, neurons are one 545 
of the most highly polarized cell types in nature (Takano et al., 2015). As in our study, DIV4 546 
PHNs do not show morphological differences when analyzed by determining the axon length, 547 
entire neurite length and neurite number. Therefore, sAPPs should not interfere with early 548 
stages in neuronal development in vitro. The observation that His-EGFP-sAPPβ-treated 549 
neurons showed different effects in Sholl analysis compared to His-EGFP-sAPPα-treated 550 
neurons, suggests that different receptors may be involved in mediating sAPPα and sAPPβ 551 
effects. Considering that, in our study, sAPPs interfered with intermediate stages (DIV7), but 552 
not with early stages (DIV4) of neuronal development in cell culture, we can assume that sAPPs 553 
affect dendritic development rather than axon specification. Since we further showed that 554 
sAPPs impact on glutamate signaling, it seems likely that functions are mediated by modulation 555 
of a subset of distinct glutamate receptors that are differentially expressed during PHN 556 
development in vitro (Janssens and Lesage, 2001) and in vivo (Luján et al., 2005). A recent 557 
study by Hasebe et al. revealed that sAPPα promotes neurite outgrowth in stage 1 neurons (24 558 
h after plating) (Hasebe et al., 2013). This finding contradicts our results to some extent, but 559 
differences might be explained by the use of another neuronal culture system (cortical neurons 560 
instead of hippocampal neurons). In fact, in line with our findings, Chasseigneaux et al. were 561 
able to demonstrate that sAPPα increases axon length in primary neurons (Chasseigneaux et 562 
al., 2011). In contrast to our findings, they observed a decrease in dendrite outgrowth. The 563 
difference could be explained by the earlier stage (DIV5 neurons from E16 mice vs. DIV7 564 
neurons from E18 mice) they examined or the investigation of cortical neurons instead of 565 
hippocampal neurons and the utilization of another mouse strain (Swiss instead of C57BL/6). 566 
Our results are also in agreement with a previous study showing that sAPPα enhances axon 567 
growth (Young-Pearse et al., 2008).   568 
Second, in this study, we show that mCherry-sAPP overexpression in PHNs results in increased 569 
glutamatergic synaptic architecture in DIV14 neurons. For precise functioning of the 570 
mammalian brain, it is crucial that neuronal contacts are formed properly and maintained in the 571 
long term, if needed. Since synaptogenesis in PHNs is dependent on neuronal activity and 572 
connectivity, amongst others, we next asked whether long-term exposure of sAPPs to PHNs 573 
impacts synaptogenesis and the formation of subsynaptic structures like the PSD. In line with 574 
our findings, that both mCherry-sAPPα and mCherry-sAPPβ overexpression led to a higher 575 
number of mature glutamatergic synapses in PHNs, Bell et al. reported that ADAM-10-576 
overexpression in mice increased the brain sAPPα levels and the number of presynaptic bouton 577 
densities (Bell et al., 2008). Other work showed that infused sAPPα increased memory retention 578 
and synaptic density in the frontoparietal cortex of rats (Roch et al., 1994). The process of 579 
synapse formation involves axo-dendritic contact after axon extension, presynaptic and 580 
postsynaptic differentiation, synaptic maturation, pruning and maintenance (Johnson-581 
Venkatesh and Umemori, 2010). At which stage sAPPs enhance synaptogenesis is not clear yet 582 
and remains to be answered. The observation that mCherry-sAPPα exposure leads to increased 583 
layer thickness of PSDs in PHN synapses, agrees with several studies investigating the effects 584 
of sAPPα on synaptic transmission and LTP (Taylor et al., 2008) or the ability of sAPPα to 585 
rescue synaptic deficits in different APP transgenic mice (Fol et al., 2015; Hick et al., 2015; 586 
Ring et al., 2007). Claasen et al. further showed, that sAPPα upregulates synaptic protein 587 
synthesis by a proteinkinase G-dependent mechanism in synaptoneurosomes prepared from rat 588 
hippocampi (Claasen et al., 2009). Based on these results, we can conclude that the sAPP-589 
induced extended neuritic arborization at DIV7 ends up in an advanced synaptic architecture of 590 
glutamatergic synapses at later stages (DIV14) of neuronal development in vitro.  591 
Third, we demonstrated that increased neuritic arborization is associated with higher levels of 592 
activated markers of neuronal activity. Development of the neuritic arbor and synaptogenesis 593 
are, inter alia, dependent on neuronal activity. To that end, we tested the hypothesis that the 594 
more sophisticated arborization at DIV7 and the advanced synaptic architecture at DIV7 upon 595 
sAPP exposure is associated with neuronal activity. We first tested whether sAPPs influence 596 
glutamate-evoked Ca2+ signals in mature PHNs. By showing that both His-EGFP-sAPPα and 597 
His-EGFP-sAPPβ (15 min preincubation) increase free intracellular Ca2+ levels upon glutamate 598 
stimulation, we concluded that sAPPs modulate glutamate sensitivity of PHNs in a short-term 599 
response. Given that a 15 min preincubation with sAPPs was enough to alter glutamate 600 
sensitivity of PHNs, a mobilization of the synaptic AMPA-R pool mediated by sAPPs is more 601 
likely than a transcription-based response. To obtain a more detailed picture of how sAPPs 602 
modulate neuronal plasticity on a molecular level, we next asked whether glutamate-activated 603 
synaptic plasticity-dependent downstream targets of Ca2+ signaling are also affected by His-604 
EGFP-sAPP exposure to neurons. Downstream components of Ca2+ are, amongst others, 605 
mitogen-activated protein kinase 1 (ERK2) and the transcription factor cyclic AMP-responsive 606 
element-binding protein 1 (CREB1). Hence, we tested whether His-EGFP-sAPPs modulate 607 
ERK2 and CREB1 phosphorylation in glutamate stimulated PHNs at different stages of 608 
development (DIV4, DIV7, DIV14). When PHNs were briefly stimulated with glutamate, we 609 
detected increased levels of p-ERK2 as well as p-CREB1 upon long-term His-EGFP-sAPP 610 
exposure to neurons until DIV7. By contrast, we did not see any differences in p-ERK2 or p-611 
CREB1 levels at DIV4 or DIV14 glutamate-stimulated PHNs when exposed to His-EGFP-612 
sAPPs compared to control. We concluded that a peak level of phosphorylated LTP-dependent 613 
kinases at DIV7 leads to increased neuritic arborization and subsequently to an advanced 614 
development of glutamatergic synapses. Unchanged levels of activated ERK2 and CREB1 at 615 
DIV4 upon His-EGFP-sAPP treatment are associated with unaltered neuritic morphology. 616 
Long-term His-EGFP-sAPP exposure to neurons did not affect p-ERK2 or p-CREB1 levels 617 
when the neuronal network was stimulated at DIV14. The latter could be a ceiling effect or a 618 
compensatory mechanism to protect neurons from overexcitation. To determine short term 619 
effects of sAPPs, we analyzed time resolution of sAPP treatment immediately after treatment 620 
in SH-SY5Y cells. We found an immediate response on CREB1 phosphorylation upon His-621 
EGFP-sAPPα treatment. These results are in line with a study by Ryan et al. showing that 622 
sAPPα induces time-dependent changes in gene expression in the rat hippocampus, amongst 623 
other downstream targets of CREB1 (Ryan et al., 2013). Our results further confirm recent 624 
findings revealing that sAPPα and sAPPβ promote Egr1/ERK1 signaling leading to enhanced 625 
axon outgrowth in vitro (Chasseigneaux et al., 2011). Moreover, a study by Rohe et al. showed 626 
that increased levels of sAPP correlated with pro-found stimulation of neuronal ERK signaling 627 
(Rohe et al., 2008). Since we have shown that sAPPs modulate glutamate induced CREB1 628 
activation, a direct modulation of one or more distinct glutamate receptor seem to be likely. 629 
However, which of glutamate receptor (or subunit composition) is modulated by sAPPs remains 630 
to be determined. At least, one study by Taylor et al. showed that sAPPα regulates hippocampal 631 
NMDA-receptor function (Taylor et al., 2008). 632 
Fourth, mCherry-sAPP overexpression led to advanced glutamatergic architecture at DIV14 633 
comparable to control-treated DIV21 neurons, but it suppresses the formation of GABAergic 634 
inputs. Since we showed, that both sAPPs positively regulate neuritic arborization and synapse 635 
formation, we determined whether the sAPP effects are a mere mechanism of advanced 636 
development. Therefore, we compared the number of inhibitory and excitatory synaptic inputs 637 
of mCherry-sAPP-treated PHNs at DIV14 with control treated DIV21 neurons. We found that 638 
the number of excitatory synaptic inputs of DIV14 PHNs exposed to mCherry-sAPPs was 639 
comparable with control-treated DIV21 neurons. In contrast, the number of inhibitory inputs in 640 
hippocampal cell culture was not decreased in the control when comparing DIV21 with DIV14. 641 
We show here for the first time that the number of inhibitory synaptic inputs, determined by 642 
VGAT immunostaining, is decreased when comparing control treated DIV14 inhibitory inputs 643 
with DIV14 mCherry-sAPP-treated inhibitory inputs. Therefore, we concluded that sAPP 644 
effects are not merely resulting from advanced neuronal development, but rather modulate the 645 
ratio of excitatory to inhibitory inputs. Since proper formation and function of neuronal circuits 646 
depends on the balance of inhibitory and excitatory mechanisms, this is an important finding. 647 
To rule out that the decrease in GABAergic input is a consequence of cell death, we tested if 648 
sAPPs impact on cell viability by the MTT assay. We found no impact of sAPP preparations 649 
on cell viability, even at high concentrations (data not shown). Interestingly, genes related to 650 
GABAergic signaling like glutamate decarboxylase 1 and 2 (GAD) or somatostatin (Sst) 651 
possess CREB1 binding sites in their promotor regions (Zhang et al., 2005). Furthermore, in 652 
patients suffering from autism spectrum disorders (ASDs), an imbalance in 653 
GABAergic/glutamatergic inputs was observed (El-Ansary and Al-Ayadhi, 2014) and 654 
increased levels of sAPPα were described in the CSF of ASD patients (Ray et al., 2011). 655 
Whether these findings correlate statistically significantly or are causative for pathophysiology 656 
remains to be determined. Our finding that neuronal complexity, synapse maturation and E/I 657 
balance are increased in PHNs upon sAPP exposure are in line with several studies focusing on 658 
BDNF effects on developing neurons (Ji et al., 2010; Singh et al., 2006). This raises the question 659 
of whether sAPP can directly/indirectly modulate or bind to TrkB receptors to induce BDNF-660 
like effects. Further studies are needed to shed light on this hypothesis. 661 
Fifth, in almost all our assays assessing the effects of sAPPs on glutamatergic development, we 662 
observed that sAPPβ effects are similar to neurotrophic sAPPα effects. These findings disprove 663 
our hypothesis that sAPPβ differs from the neurotrophic effects on the developing 664 
glutamatergic system of sAPPα. Differences between sAPPα and sAPPβ were seen in the Sholl 665 
analysis that revealed a distinct pattern of ramification for sAPPα and sAPPβ, with increased 666 
branching close to the soma for sAPPα. In contrast to sAPPα-treated neurons, sAPPβ exposure 667 
did not lead to axon elongation. Furthermore, sAPPβ-treated neurons did not show increased 668 
PSD layer thickness or ERK phosphorylation, whereas sAPPα-treated neurons did. 669 
Interestingly, a study by Furukawa et al. could show that sAPP was approximately 100-fold 670 
more potent than sAPP in protecting hippocampal neurons against excitotoxicity, A toxicity, 671 
and glucose deprivation (Furukawa et al., 1996b). The main domains described to mediate the 672 
neurotrophic effects of sAPPα are shared by sAPPβ, except for the last 16 c-terminal amino 673 
acids. This would favor a model where the common parts of sAPPα and sAPPβ mediate the 674 
observed functions. Other functions might be affected differentially as a study by Peters-Libeu 675 
et al. indicated that, despite the large sequence homology between both sAPPs, the folding is 676 
different, leading to different effects on APP cleavage by BACE1 (Peters-Libeu et al., 2015). 677 
If sAPPα and sAPPβ bind (e.g. depending on their folding) to the same or distinct receptors to 678 
mediate their functions remains elusive. 679 
Finally, we observed that sAPPα is significantly decreased in human AD brains and detectable 680 
in human synaptoneurosomes compared to control subjects. Until now, almost all studies 681 
investigating the protein levels of sAPPs in human CNS used CSF as sample material 682 
(Colciaghi et al., 2004; Hock et al., 1998; Lannfelt et al., 1995; Palmert et al., 1990). We show 683 
here for the first time, that sAPPα is significantly decreased in AD brains and abundant in 684 
human synaptoneurosomes in AD patients and control subjects. Moreover, we observed a 685 
reduction in sAPP levels in human synaptoneurosomes from AD patients compared to control 686 
subjects by trend. Both confirmed studies which found decreased sAPPα levels in CSF of AD 687 
patients (Colciaghi et al., 2004; Hock et al., 1998; Lannfelt et al., 1995; Palmert et al., 1990). 688 
The sAPPβ antibody used in our study was not suitable to detect full length sAPPβ. For this 689 
reason, it remains to be determined if sAPPβ is also altered in AD brains. Since we 690 
demonstrated several crucial effects of sAPPα and sAPPβ in neuronal development, reduced 691 
sAPPα levels in brains of AD patients could have deleterious effects beyond Aβ 692 
pathophysiology, e.g. due to decrease of specific neurotrophic or neuroprotective mechanisms. 693 
Furthermore, altered sAPP levels in the developing brain might contribute to selective 694 
vulnerability of hippocampal neurons and therefore accelerating disease progression, e.g. by 695 
interfering with neuronal cell-type specification mechanisms (Götz et al., 2009). Disturbances 696 
in adult neurogenesis might be another explanation of how altered sAPP levels can account for 697 
AD pathophysiology (Lazarov and Demars, 2012; Lazarov and Marr, 2010; Wang et al., 2014). 698 
Taken together, our study confirmed previous findings describing neurotrophic effects for 699 
sAPPα and revealed that human recombinant sAPPβ effects resemble sAPPα effects, but to a 700 
lesser extent. We further showed that neurotrophic effects of both sAPPs in early PHN 701 
development are associated with advanced glutamatergic development and revealed that sAPPs 702 
lead to altered E/I balance in mature hippocampal neurons (Fig. 4F). Synaptic impairments 703 
observed in AD patients might be a consequence not only of Aβ accumulation, but also to the 704 
loss of synapse-promoting abilities of sAPPα and sAPPβ. Our data indicate critical stage-705 
dependent roles of both sAPPs in the developing glutamatergic system in vitro, and thus lead 706 
to a better understanding of deleterious consequences of altered APP shedding in AD patients 707 
and BACE-1 inhibitor recipients.  708 
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Figure Legends 979 
 980 
Figure 1: Morphological analysis of primary hippocampal neurons upon His-EGFP-sAPP 981 
treatment at DIV4 and DIV7. DIV2 PHNs were treated with 100nM His-EGFP-sAPPα or 982 
His-EGFP-sAPPβ and fixed and stained at DIV4 (A-C) or DIV7 (D-H). A) Boxplots comparing 983 
primary axon lengths of PHNs treated with control peptide and His-EGFP-sAPP treated 984 
neurons. Statistical analysis revealed that there is no statistically significant difference between 985 
His-EGFP-control and His-EGFP-sAPP treated groups. p < 0.05, One-Way ANOVA, Kruskal-986 
Wallis Test. B) Boxplots comparing entire neurite lengths of PHNs treated with His-EGFP-987 
control peptide and His-EGFP-sAPP treated neurons. Statistical analysis revealed that there is 988 
no statistically significant difference between control and His-EGFP-sAPP treated groups. p < 989 
0.05, One-Way ANOVA, Kruskal-Wallis Test. C) Boxplots comparing neurite numbers of 990 
PHNs treated with His-EGFP-control peptide and His-EGFP-sAPP treated neurons. Statistical 991 
analysis revealed that there is no statistically significant difference between His-EGFP-control 992 
and His-EGFP-sAPP treated groups. p < 0.05, One-Way ANOVA, Kruskal-Wallis Test. D) 993 
Boxplots comparing primary axon lengths of PHNs treated with His-EGFP-control peptide and 994 
His-EGFP-sAPP treated neurons. Statistical analysis revealed that there is a statistically 995 
significant difference between His-EGFP-control and His-EGFP-sAPPα treated group. p < 996 
0.05, One-Way ANOVA, Kruskal-Wallis test. E) Boxplots comparing entire neurite lengths of 997 
PHNs treated with His-EGFP-control peptide and His-EGFP-sAPP treated neurons. Statistical 998 
analysis revealed that there is a statistically significant difference between His-EGFP-control 999 
and His-EGFP-sAPPα as well as His-EGFP-sAPPβ treated groups. p < 0.05, One-Way 1000 
ANOVA, Kruskal-Wallis Test. F) Boxplots comparing neurite numbers of PHNs treated with 1001 
His-EGFP-control peptide and His-EGFP-sAPP treated neurons. Statistical analysis revealed 1002 
that there is a statistically significant difference between His-EGFP-control and His-EGFP-1003 
sAPPα as well as His-EGFP-sAPPβ treated groups. p < 0.05, One-Way ANOVA, Kruskal-1004 
Wallis Test. G) Representative diagram view of sholl analysis of dendritic complexity from 1005 
PHNs. H) Sholl analysis of dendritic complexity of PHNs treated with His-EGFP-control 1006 
peptide or His-EGFP-sAPPα (upper plot) / His-EGFP-sAPPβ (lower plot). Each group 1007 
comprises N=60 neurons from 3 independent cultures (~180 neurons in total for Fig. 1 A-F and 1008 
~60 neurons in total for Fig. 1 H). Asterisks indicate a statistically significant difference 1009 
between His-EGFP-control and His-EGFP-sAPP treated groups. *p < 0.05, **p < 0.01, ***p < 1010 
0.001, position wise Wilcoxon-test (26 tests, Bonferroni correction for multiple testing). 1011 
Overall differences of curves are tested with the CuCompare software. 1012 
Figure 2: Advanced glutamatergic architecture upon mCherry-sAPP overexpression. 1013 
PHNs were lentiviral transduced at 2DIV with either mCherry-control, mCherry-sAPPα or 1014 
mCherry-sAPPβ virus. A) Exemplary hippocampal neuron picture of mCherry-control, 1015 
mCherry-sAPPα and mCherry-sAPPβ transduced neurons. Neurons were fixed at DIV14 and 1016 
stained with Homer1 (red) and Bassoon (green) antibodies. Colocalizations indicating a mature 1017 
glutamatergic synapse were counted and normalized to 10µm dendrite length. Scale bar: 10µm 1018 
B) Statistical analysis revealed a significant higher number of Homer1/Bassoon colocalizations 1019 
upon mCherry-sAPPα as well as mCherry-sAPPβ overexpression. p < 0.0001, Kruskal-Wallis 1020 
test. 180 neurons from 3 independent cultures were analyzed for each condition. C) Analysis of 1021 
Homer1/Bassoon colocalizations after mCherry-control, mCherry-sAPPα or mCherry-sAPPβ 1022 
overexpression (plotted according to cumulative frequency) revealed that mCherry-sAPPα as 1023 
well as mCherry-sAPPβ lead to a homogenous rightward shift in the frequency curve. D) 1024 
Exemplary images of synaptic ultrastructure of mCherry-control, mCherry-sAPPα and 1025 
mCherry-sAPPβ overexpressing hippocampal DIV14 neurons obtained by transmission 1026 
electron microscopy. Asterisks indicate the postsynaptic density. Scale bar: 100 nm. E) 1027 
Statistical analysis revealed a significant increase of postsynaptic density layer thickness of 1028 
mCherry-sAPPα exposed neurons. p < 0.0001, Kruskal-Wallis test. 60 PSDs from three 1029 
independent cultures were analyzed for each condition F) Analysis of layer thicknesses of PSDs 1030 
after mCherry-control, mCherry-sAPPα or mCherry-sAPPβ overexpression (plotted according 1031 
to cumulative frequency) revealed that mCherry-sAPPα lead to a rightward shift in the 1032 
frequency curve.  1033 
Figure 3: Glutamate sensitivity of DIV7 PHNs is increased upon His-EGFP-sAPP 1034 
treatment. A) 15 minutes pre-Incubation of PHNs with both His-EGFP-sAPPα and His-EGFP-1035 
sAPPβ (1 nM) increase the Ca2+-influx in DIV14 PHNs upon glutamate (10 µM) stimulation. 1036 
n=3, N=18 wells; p < 0.05, Two-Way ANOVA, Dunnett‘s  post hoc test. B-C) DIV2 PHNs 1037 
were treated with 100nM His-EGFP-sAPPα or His-EGFP-sAPPβ and stimulated with 10 µM 1038 
glutamate at DIV4, DIV7 or DIV14 respectively. To determine phospho ERK2 (lower bands) 1039 
and phospho CREB1 levels Western blots were quantified by densitometric analysis. p-ERK2 1040 
levels were normalized to t-ERK2 levels and p-CREB1 levels were normalized to total levels 1041 
of CREB1 B) Relative protein levels of p-ERK2 were significantly increased upon His-EGFP-1042 
sAPPα treatment at DIV7. p = 0.02 Kruskal-Wallis Test. n=3 independent cultures. p-ERK2/t-1043 
ERK2 ratio was not significantly altered upon His-EGFP-sAPP treatment and glutamate 1044 
stimulation at DIV4 and DIV14. C) Relative protein levels of p-CREB1 were significantly 1045 
increased upon His-EGFP-sAPPα treatment and increased by trend after His-EGFP-sAPPβ 1046 
treatment at DIV7. His-EGFP-sAPPα vs His-EGFP-control: p = 0.001, His-EGFP-sAPPβ vs. 1047 
His-EGFP-control: p = 0.056. Kruskal-Wallis test. n=3 independent cultures, at least three 1048 
technical replicates per culture. P-CREB1/t-CREB1 ratio was not significantly altered upon 1049 
His-EGFP-sAPP treatment and glutamate stimulation at DIV4 and DIV14. 1050 
Figure 4: mCherry-sAPP overexpression lead to advanced glutamatergic architecture at 1051 
DIV14 comparable to control treated DIV21 neurons but it suppresses the formation of 1052 
GABAergic inputs. PHNs were lentiviral transduced at DIV2 with either mCherry-control, 1053 
mCherry-sAPPα or mCherry-sAPPβ virus. mCherry-sAPP treated neurons were fixed and 1054 
stained at DIV14. mCherry-Control treated neurons were fixed and stained and DIV14 and 1055 
DIV21. A) Exemplary PHN dendrites after overexpression of control construct and fixed at 1056 
DIV14 and DIV21 and overexpression of mCherry-sAPPα or mCherry-sAPPβ fixed at DIV14. 1057 
Presynapses were stained by VGlut1 antibodies. B) Statistical analysis revealed a significant 1058 
higher number VGLUT1 positive puncta (presynaptic marker) upon mCherry-sAPPα as well 1059 
as mCherry-sAPPβ overexpression. PHNs overexpressing the control construct p < 0.0001, 1060 
Kruskal-Wallis test. 60 neurons from 3 independent cultures were analyzed for each condition. 1061 
C) Exemplary PHN dendrites after overexpression of control construct and fixed at DIV14 and 1062 
DIV21 and overexpression of mCherry-sAPPα or mCherry-sAPPβ fixed at DIV14. Presynapses 1063 
were stained by VGAT antibodies. B) Statistical analysis revealed a significant higher number 1064 
VGAT positive puncta (presynaptic marker) upon mCherry-sAPPα as well as mCherry-sAPPβ 1065 
overexpression. PHNs overexpressing the control construct p < 0.0001, Kruskal-Wallis test. 60 1066 
neurons from 3 independent cultures were analyzed for each condition. E) The E/I ratio was 1067 
calculated by dividing the average number of VGlut1 pos. puncta by the average number of 1068 
VGAT pos. puncta along 10 µm dendrite length. The foldchange over control was calculated 1069 
and plotted. E/I ratio at DIV14 of mCherry-sAPPα as well as mCherry-sAPPβ treated neurons 1070 
is significantly increased compared to mCherry-control treated neurons. When comparing 1071 
DIV14 control treated neurons with DIV21 mCherry-control treated neurons, no significant 1072 
change was observed.  p < 0.0001, One-Way ANOVA, Kruskal-Wallis test, Dunn’s post-hoc 1073 
test. F) Schematic diagram for proposed functions of sAPPs in modulating glutamatergic 1074 
development in PHNs. 1075 
Figure 5: sAPPα levels are significantly reduced in brain homogenates of AD patients. A) 1076 
Qualitative Western blot analysis of 14 human brains (seven control and seven AD brains) 1077 
revealed that sAPPα is detectable by a specific sAPPα antibodies in human brain homogenates 1078 
and that sAPPα levels are significantly lower in AD brain homogenates compared to control 1079 
subjects. p = 0.007, Mann-Whitney U-test. B) Enrichment of synaptic fraction showed that 1080 
sAPPα are detectable in the corresponding synaptic pellets and a trend of reduced sAPPα levels 1081 
in AD synaptoneurosomes compared to control subjects was observed. p = 0.128, Mann-1082 
Whitney U-test. Western blots were quantified by densitometric analysis. 1083 
Figure S1: Qualitative analysis of recombinant His-EGFP-sAPPs produced in Flp-In-1084 
HEK293 cells and by using a lentiviral system reveals no cross contamination between 1085 
sAPPα and sAPPβ production A) Simply blue safe stained SDS-PAGE gel showing no side 1086 
bands in His-EGFP-sAPPα and His-EGFP-sAPPβ elutions (His purification from HEK293 cell 1087 
supernatant). B) Corresponding Western Blot to stained SDS-PAGE gel. The upper blot shows 1088 
bands detected with an anti β-Amyloid antibody (6e10). In the His-EGFP-sAPPα elution lane 1089 
a band at ~120 kDa can be detected, whereas no band is visible in the His-EGFP-sAPPβ elution 1090 
lane. The lower blot shows bands detected with an antibody directed against the n-terminus of 1091 
APP (22c11). There are bands at ~120 kDa visible in the His-EGFP-sAPPα and His-EGFP-1092 
sAPPβ elution lane. C) Western Blots showing the supernatant of DIV14 PHNs upon sAPP 1093 
lentiviral transduction at DIV2. The left blot shows a band detected with an anti β-Amyloid 1094 
antibody (6e10) in the supernatant of mCherry-sAPPα transduced neurons. The right blot shows 1095 
bands detected with an antibody directed against the n-terminus of APP (22c11) in the 1096 
supernatant of mCherry-sAPPα and mCherry-sAPPβ transduced neurons. No band is visible in 1097 
the supernatant of mCherry-pUltra hot transduced neurons. D) Schematic illustration of 1098 
specificity of the used antibodies for the qualification of recombinant sAPP production. 1099 
Figure S2: Exemplary images of DIV4 and DIV7 PHNs used for morphometric analysis 1100 
upon control peptide and His-EGFP-sAPP treatment. A-C) PHNs were treated with control 1101 
peptide or His-EGFP-sAPPs at DIV2 and stained at DIV4 with an anti-beta-III-tubulin antibody 1102 
to assess the morphology of His-EGFP-control (A), His-EGFP-sAPPα (B) and His-EGFP-1103 
sAPPβ (C) treatment. D-F) PHNs were treated with His-EGFP-control peptide or His-EGFP-1104 
sAPPs at DIV2 and stained at DIV7 with anti-tau (red) and anti-MAP2 antibodies (green) to 1105 
assess the morphology of His-EGFP-control (D), His-EGFP-sAPPα (E) and His-EGFP-sAPPβ 1106 
(F) treatment. Scale bars: 100µm. 1107 
Figure S3: His-EGFP-sAPPα increases CREB-1 phosphorylation in SH-SY5Y cells in a 1108 
time-dependent manner. A) Ratiometric analysis of Venus and mTurquoise fluorescence 1109 
intensities shows a significant increase of CREB-1 phosphorylation in SH-SY5Y cells upon 1110 
His-EGFP-sAPPα pre-treatment (1nM). CREB phosphorylation was determined by the CREB-1111 
phosphorylation biosensor ICAP. Cells were stimulated with 10M glutamate and 1112 
Venus/mTurquoise intensities ratios were recorded after 5, 12, 19, 24, 30, 35, 40, 45, 50, 55 1113 
and 60 minutes. B) Ratiometric analysis of Venus and mTurquoise fluorescence intensities 1114 
shows no alterations of CREB-1 phosphorylation in SH-SY5Y cells upon His-EGFP-sAPPβ 1115 
pre-treatment (1nM). CREB phosphorylation was determined by the CREB-phosphorylation 1116 
biosensor ICAP. Cells were stimulated with 10M glutamate and Venus/mTurquoise intensities 1117 
ratios were recorded after 5, 12, 19, 24, 30, 35, 40, 45, 50, 55 and 60 minutes. His-EGFP-control 1118 
group (N=21), His-EGFP-sAPPα (N=11), His-EGFP-sAPPβ (N=21). Asterisks indicate a 1119 
statistically significant difference between His-EGFP-control and His-EGFP-sAPPα treated 1120 
groups. *p < 0.05, **p < 0.01, ***p < 0.001, position wise Wilcoxon-test (12 tests, Bonferroni 1121 
correction for multiple testing). Overall differences of curves are tested with the CuCompare 1122 
software. 1123 
Figure S4: sAPPβ is not detectable in human brain homogenates. Western blot showing 1124 
sAPPβ cleavage fragments. Full length sAPPβ at 90-100 kDA molecular weight is not 1125 
detectable. 1126 
 1127 
 1128 
Table S1: Patient demographic data 1129 
Edinburgh brain bank 
number 
BBN 
NUMBER 
Gender diagnosis Age[y] 
SD001/16 28406 M control 79 
SD017/16 28793 F control 79 
SD018/16 28794 F control 79 
SD024/15 26495 M control 78 
SD051/15 19597 M control 79 
SD032/13 16425 M control 61 
SD063/13 19686 F control 77 
SD049/14 24322 M AD 80 
SD055/14 24526 M AD 79 
SD056/14 24527 M AD 81 
SD007/15 25056 M AD 72 
SD014/15 25739 F AD 85 
SD040/15 26718 M AD 78 
SD005/16 28410 F AD 62 
M = male, F = female 1130 
 1131 
 1132 
Supplementary Methods: 1133 
Measurement of the time-dependent phosphorylation of CREB1 1134 
To measure the time-dependent phosphorylation of CREB1 SH-SY5Y cells were transfected 1135 
with a FRET based indicators of phosphorylation for CREB1 (pNLS- mTurquoise2Δ-11AA-1136 
ICAP- td_cp173Venus(d)_188_NES-pUltraHot) (Friedrich et al., 2010; Klarenbeek et al., 1137 
2015). On the day before the transfection SH-SY5Y cells were seeded onto a 96 Well Black 1138 
Clear Flat Bottom TC-Treated Microplate (Corning, New York, USA) at a density of 4x104 1139 
cells per well. The cells were incubated overnight at 37 ° C and 5% CO2 in 10 ml DMEM plus 1140 
10 % fetal calf serum and 1 % Penicillin with Streptomycin and are transfected the next morning 1141 
according to the manufacturer's instructions of the LTX & Plus Reagent Kit. After another 24 1142 
hours of incubation under the same conditions the cells were used for measurements in the 1143 
microplate reader. To carry out the experiments the medium must be replaced by a clear wash 1144 
buffer (for buffer composition see FLIPR-analysis part in Material & Methods section) which 1145 
does not influence the fluorescence intensity to be measured. The 96 well plate was then placed 1146 
in the to 37 ° C preheated Clariostar microplate reader (BMG Labtech, Ortenberg, Germany). 1147 
In the reader, the cells were excited with a wavelength of 430 nm and the emission is measured 1148 
at 480 nm and 550 nm. The first emission wavelength corresponds to the range in which 1149 
mTurquoise2Δ emits, the second wavelength is slightly above the emission of the Venus 1150 
fluorophore (530 nm) to avoid a blend with the emitting light of turquoise. Other important 1151 
measurement settings are: focal height 3.8 mm, bottom reading and well scan with a 5x5 matrix. 1152 
First the fluorescence intensities of the untreated cells were measured. Subsequently, the cells 1153 
were treated with glutamate (final concentration 10 μM) and the fluorescence intensity was 1154 
measured again at 5, 12, 19, 24, 30, 35, 40, 45, 50, 55 and 60 minutes after stimulation for the 1155 
measurements of CREB-activity. For the measurements, the cells were pretreated with His-1156 
EGFP-sAPPα/β / His-EGFP-control peptide (1nM) for 24 h. The analysis of the measured 1157 
fluorescence intensities was performed with the Clariostar Data Analysis software (BMG 1158 
Labtech, Ortenberg, Germany). For the evaluation, the fluorescence intensity of Venus 1159 
(detection at 550 nm) was set in relation to the fluorescence intensity of Turquoise (detection 1160 
at 480 nm), the ratio was then standardised to the fluorescence ratio of the untreated and 1161 
unstimulated cells. 1162 
